Literature DB >> 34253648

Combining C reactive protein and serum albumin to predict 90-day mortality in systemic lupus erythematosus with serious community-acquired infections.

Shuangjun He1, Chao Tang1, Jie Yu1, Jun Ma1, Minjie Qiao1, Wei Zhou1, Yi Chen1, Xingyu Zhang2.   

Abstract

OBJECTIVE: Serious infections in SLE are common and have emerged as the major cause of death. However, effective methods to identify poor prognosis are still lacking. Therefore, we aimed to determine the predictive value of C reactive protein (CRP) plus albumin (ALB) in SLE with serious infections.
METHODS: From May 2015 to December 2018, consecutive patients with SLE presenting with serious infections in our emergency department were prospectively recruited. Serum CRP and ALB were measured within 24 hours of admission. The outcome was defined as mortality rate at 90 days. A CRP plus ALB score (2-6) was assigned based on the CRP and ALB concentrations. We performed univariate and multivariate regression analyses to detect the independent effects of CRP plus ALB on 90-day mortality (all-cause and infection-related). Subgroup analyses were used to show the effects stratified by lupus nephritis.
RESULTS: A total of 150 patients were included, and the all-cause 90-day mortality rate was 38% (n=57), 41 of which was infection-related. The predominant infection sites were pulmonary (79.3%) and bloodstream infection (20.7%). Serum CRP and ALB levels were significantly different in non-surviving patients compared with those in surviving patients (p=0.002 and p<0.001, respectively). In the fully adjusted logistic regression model, the CRP plus ALB score was associated with decreased 90-day survival (adjusted OR 1.52; 95% CI 1.08 to 2.13; p=0.017).
CONCLUSIONS: CRP plus ALB was associated with the risk of all-cause and infection-related 90-day mortality in SLE with serious infections. Although this finding requires further verification, the two parameters may be useful for predicting poor outcomes in such patients. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  health care; inflammation; lupus erythematosus; outcome assessment; systemic

Year:  2021        PMID: 34253648     DOI: 10.1136/lupus-2021-000505

Source DB:  PubMed          Journal:  Lupus Sci Med        ISSN: 2053-8790


  2 in total

1.  Serum amyloid A-to-albumin ratio as a potential biomarker to predict the activity, severity, and poor prognosis of systemic lupus erythematosus.

Authors:  Liang Zhao; Qun Zhang; Zhigang Feng; Jinshan Zhang; Feng He
Journal:  J Clin Lab Anal       Date:  2022-02-10       Impact factor: 2.352

2.  Prognostic Value of Routinely Measured Inflammatory Biomarkers in Older Cancer Patients: Pooled Analysis of Three Cohorts.

Authors:  Nadia Oubaya; Pierre Soubeyran; Nicoleta Reinald; Marianne Fonck; Mylène Allain; Sonia Zebachi; Damien Heitz; Marie Laurent; Cécile Delattre; Philippe Caillet; Jérôme Dauba; Sylvie Bastuji-Garin; Gilles Albrand; Michael Bringuier; Muriel Rainfray; Etienne Brain; Thomas Grellety; Elena Paillaud; Simone Mathoulin-Pélissier; Carine Bellera; Florence Canouï-Poitrine
Journal:  Cancers (Basel)       Date:  2021-12-07       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.